Krystal Biotech, Inc.
KRYS
Peringkat dalam Saham
#2123
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Harga Saham
$322.07
Terakhir disinkronkan: 2026-10-21
Kapitalisasi Pasar
$9.53B
Perubahan (1 hari)
-1.03%
Perubahan (1 tahun)
72.76%
Negara
US
Perdagangan Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Riwayat harga saham Krystal Biotech, Inc. (KRYS)
Harga penutupan tertinggi: $326.06 pada 2026-10-01
Harga penutupan terendah: $10.08 pada 2017-09-01
Harga penutupan terendah: $10.08 pada 2017-09-01
Riwayat harga saham Krystal Biotech, Inc. dari 2017 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 20.87% |
| 2025 | 39.10% |
| 2024 | 50.07% |
| 2023 | 49.77% |
| 2022 | 7.69% |
| 2021 | 22.40% |
| 2020 | -4.80% |
| 2019 | 169.14% |
| 2018 | 129.54% |
| 2017 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
